Literature DB >> 29984458

Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis.

Vianney Gruzelle1, Marion Ramassamy1, Cristina Bulai Lidiveanu2, Alain Didier1, Claire Mailhol3, Laurent Guilleminault1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29984458     DOI： 10.1111/all.13557

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  3 in total

Review 1.  Treatment of Indolent and Advanced Systemic Mastocytosis.

Authors:  Alessandro Buonomo; Eleonora Nucera; Marianna Criscuolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level.

Authors:  Ali Selcuk; Abdullah Baysan
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

Review 3.  Clinical Utility of Rush Venom Immunotherapy: Current Status.

Authors:  Vianney Gruzelle; Claire Mailhol; David W Waters; Laurent Guilleminault
Journal:  J Asthma Allergy       Date:  2020-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.